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Survival estimates stratified by the
Nottingham Prognostic Index for early
breast cancer: a systematic review and
meta-analysis of observational studies
Ewan Gray1*, Anna Donten2, Katherine Payne2 and Peter S. Hall1
Abstract
Background: Estimates of survival for women diagnosed with early staged breast cancer are available based on
stratification into prognostic categories defined using the Nottingham Prognostic Index (NPI). This review aimed to
identify and summarize the estimated survival statistics from separate sources in the literature and to explore the
extent of between-study heterogeneity in survival estimates.
Methods: Observational studies in women diagnosed with early and locally advanced breast cancer reporting
overall survival by NPI category were identified using a systematic literature search. An exploratory meta-analysis
was conducted to describe survival estimates and assess between-study heterogeneity.
Results: Twenty-eight studies were identified. Nineteen studies with sufficient data on overall survival were included in
meta-analysis. A high level of heterogeneity in survival estimates was evident with I2 values in the range of 90 to 98%.
Conclusions: The substantial differences between studies in the relationship between NPI categories and survival at 5
and 10 years poses challenges for use of this prognostic score in both clinical settings and in decision-analytic model-
based economic evaluations.
Keywords: Breast cancer, Prognosis, Precision medicine, Meta-analysis, Nottingham Prognostic Index
Background
The Nottingham Prognostic Index (NPI) is a commonly
used, clinically relevant and internationally validated [1, 2]
system for classifying early and locally advanced breast
cancer cases (TNM stages I, II, and III [3]) into three or
more prognostic groups [4, 5]. Although more advanced
models [6, 7] have superseded NPI in some applications, it
continues to have an active role in clinical practice and
research [8]. In clinical practice, NPI and related prognos-
tic models have an important application for patients and
clinicians to inform the decision of whether or not to
undergo adjuvant chemotherapy following surgery [9],
an early example of what is commonly called preci-
sion medicine [10].
The NPI can be used to provide prognostic informa-
tion by assigning individuals into prognostic categories
and then applying the survival estimates from a previous
cohort study [11]. As well as providing prognostic esti-
mates for individual patients, the NPI is useful in the
context of economic evaluations. In economic evaluation
of new interventions, overall survival is a key input for
decision-analytic models designed to quantify the incre-
mental costs and benefits and inform if, and how, to
allocate finite healthcare budgets towards new screening
and management options [12]. Decision-analytic models
have a key role in the evaluation of new technologies
when clinical trials are not likely to be feasible or timely
in terms of producing robust evidence of the impact of
introducing new programmes or changing existing pro-
grammes [13].
The NPI categories are a linear combination of three
prognostic factors: tumour size (maximum diameter in
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millimetres), histological grade (1- to 3-point scale) and
lymph node staging (1- to 3-point scale). Standardized
published cut-offs (see Additional file 1: Appendix 1) are
used to form prognostic categories within a population
(e.g. good, moderate and poor prognostic groups).
This study aimed to identify and describe all published
observational studies reporting NPI-category-specific
overall survival following a diagnosis of early and/or
locally advanced breast cancer. A meta-analysis was used
to explore the between-study heterogeneity in survival
estimates.
Methods
A systematic review and meta-analysis, following pub-
lished recommendations [14, 15], were used to identify
all published cohort studies investigating the survival of
early and locally advanced breast cancer patients strati-
fied into prognostic groups using the NPI and to
synthesize the results. This systematic review was not
registered with PROSPERO.
Data sources and searches
Two databases (Embase: date of inception 1974 to 9
November 2016; MEDLINE: date of inception 1946 to 9
November 2016) were searched using bespoke electronic
search strategies (see Additional file 1: Appendix 2) in-
formed by search criteria designed by Nelson et al. [16].
Hand searching of reference lists of included studies was
also undertaken.
Study selection
Retrieved titles and abstracts were screened independ-
ently by two reviewers (EG, AD) in accordance with the
inclusion and exclusion criteria. The review includes all
cohort studies1 of women with early or locally advanced
breast cancer, reporting all-cause mortality (overall sur-
vival) stratified by NPI group. Only journal articles or
reports published in English were included. Studies were
excluded if they were limited to only a specified
sub-group of the full population (e.g. HER-2-positive
patients only) or if they included patients with recurrent
cancer2 or ductal carcinoma in situ.3 To be included in
the meta-analysis, a study must have reported survival
estimates as tables of survivors/events per year or graph-
ically as survival curves.
Quality assessment and data extraction
The Critical Appraisal Skills Programme (CASP) Cohort
Study Checklist [17] was used to appraise the reporting
quality of the selected studies (see Additional file 1:
Appendix 3). The following data were extracted and
tabulated by two reviewers: study setting, sample de-
scription, methods of analysis and survival estimates
(‘overall survival’). Overall survival data were presented
in identified studies as tables or graphs. Survival data
from the studies using graphs were extracted using
visual assessment. Guyot et al. suggest the use of
algorithms for extracting data from digitized curves and
conversion to time-to-event data using inverted
Kaplan-Meier equations. Guyot et al.’s method was not
used in this study because it requires more detailed
reporting of numbers at risk (at multiple time points)
than what was generally available in the included studies.
Annual survival estimates and initial sample sizes were
used recorded (see Additional file 1: Appendix 4 for fur-
ther details of data extraction). Reconstruction of indi-
vidual level time-to-event data from published survival
curves has been suggested to improve the precision of
meta-analysis of survival estimates. The advantages are
that is potentially possible to include information
regarding the censoring of observations [18] and com-
bine survival data reported over differing lengths of
follow-up.
Data analysis
All statistical analyses were conducted using Stata version
14. Forest plots were used to present individual study sur-
vival estimates for both 5 years and 10 years of follow-up.
These are ordered from most distant to most recent year
of mid-point of data collection. Meta-analysis, using both
fixed and random effects [19] models, produced pooled
estimates of both 5-year and 10-year survival, for each
NPI category separately, and allowed calculation of
between-study heterogeneity statistics.
Heterogeneity between-study included datasets was
assessed primarily using the I2 statistic because the inter-
pretation is appropriate and useful from an exploratory
and hypothesis generating perspective [20]. This statistic
is an approximate measure of what part of the variance
between the estimated effects in the meta-analysis is
caused by study heterogeneity rather than sampling
error. An I2 score over 75% is typically taken to indicate
high heterogeneity. The statistic describes the observed
heterogeneity and should not be used to make inference
regarding the range of true effects [21]. The Q statistic
provides a statistical test of the null hypothesis that
studies are homogenous (all estimating the same true
effect). However, it should be noted that statistical test
may be an underpowered test for heterogeneity when
the number of studies is small [22].
The tau statistic was also considered, which provides
an estimate of the between-study standard deviation in
the true effects within a random effects meta-analysis
framework [23]. The choice between using the fixed
effects or the random effects meta-analysis depends on
the assumed perspective regarding the underlying true
effect(s) and the desired interpretation of the precision
weighted average survival estimate [24]. Assumptions
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about the underlying true effects for these data are dis-
cussed in the terminology of Spiegelhalter et al. [25]:
‘identical parameters’, ‘independent parameters’ or ‘ex-
changeable parameters’. The ‘identical parameters’
assumption is probably unrealistic in this setting given
the diversity in study circumstances. Assuming ‘inde-
pendent parameters’ may be reasonable if the variation
between studies is caused by a variety of unique differ-
ences in specific settings, and the ‘exchangeable parame-
ters’ assumption may also be reasonable if the variation
between studies can be described by a single mixing dis-
tribution. An independent parameters assumption would
motivate a fixed effects meta-analysis, while exchange-
able parameters would motivate a random effects
meta-analysis. In this exploratory study, we are ambiva-
lent about which of these assumptions is the most
appropriate, believing both may be reasonable, and
therefore present both fixed and random effects
estimates.
Results
A total of 28 studies were suitable for inclusion in the
review (see Fig. 1) and 19 of these studies were included
in the meta-analysis (see Table 1). Of the 28 studies, two
studies [2, 26] provided the results of survival analysis
for two data series; therefore, a total of 30 datasets were
included in the review and 20 in the meta-analysis.
Three studies [27–29] provided only data up to 5-year
survival and were excluded from the meta-analysis of
10-year survival. Nine studies (containing ten datasets)
were excluded from any kind of meta-analysis due to the
following reasons. The quality of the graphical presenta-
tion in two studies [30, 31] did not allow for extraction
of the survival data. Three further studies [2, 32, 33] did
not report numbers of patients in each NPI category.
One [34] used different cut-off points for NPI that
meant the categories were not comparable with the
majority of the studies. Two studies [35, 36] reported
insufficient data. One study [37] excluded patients who
died in the first months after the surgery, and therefore,
the provided survival estimates were incomplete. Eight
data series from seven studies [1, 5, 26, 38–41] reported
results from the original Nottingham case series and/or
West Midlands Cancer registry (to which Nottingham
contributes). These studies report partially overlapping co-
horts of patients (see Fig. 2). To minimize ‘double-count-
ing’, four studies were excluded from the meta-analysis
which meant that the remaining included studies [1, 5, 41]
contained minimal overlap in the reported cohorts.
Among the remaining studies, Blamey et al. [1] does over-
lap with Allgood et al. [41]; however, the proportion of
data that was shared was a relatively small proportion of
Fig. 1 Study selection process
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the data because the first study reports a pooled European
cohort of which approximately 15% of the data is from
Nottingham, while the second study reports data from the
West Midlands Cancer Registry to which Nottingham
contributes only a minority of cases.
Description of studies
The earliest data reported in the published studies
came from 1970 [42] and most recent data from 2014
[43] (see Fig. 2). Fourteen of the identified data series
(47%) reported UK data. Ten studies reported data
from other European countries, and one study [1] re-
ported data from ten European countries, including
the UK. One study [2] compared two datasets: from
Finland and the USA. Single studies reported data
from each of Canada [42], Japan [35], South Korea
[32], Hong Kong [27] and Iran [43]. Study reporting
quality was generally assessed as satisfactory, and risk
of bias in relation to the study survival estimates was
considered to be low for all included studies (see
Additional file 1: Appendix 3).
Start of each line represents first time point of data
collection, and arrow head represents last time point of
data collection for each study dataset.
Systematic review of evidence
There was diversity between the included studies in how
women with breast cancer were classified by NPI cat-
egory. The majority of the studies (n = 18; 60%) used
three NPI-categories. Two studies [29, 44] (7%) grouped
the sample into five NPI categories. The remaining ten
(33%) studies used other numbers of NPI groups ranging
from four to ten (see Table 1). Given the majority of
studies used three NPI categories, the data from all stud-
ies were aggregated into three groups collapsing NPI
categories where necessary. Three studies [30, 42, 45]
did not provide cut-off points for NPI categories, and it
was, therefore, assumed these studies used the standard
cut-off values: NPI less than 3.4 for ‘good prognostic
group’, between 3.4 and 5.4 for ‘moderate prognostic
group’ and greater than 5.4 for ‘poor prognostic group’.
Two studies [28, 41] provided different cut-off points. It
was assumed that observations with NPI less than 3.41
belong to the good prognostic group and observations
with NPI less than 5.41 in the Jarman et al. [28] study
and NPI less than 5.28 in Allgood et al. [41] study be-
long to the moderate prognostic group.
Figures 3 and 4 report the percentage of women
surviving with breast cancer at two time points,
5 years and 10 years respectively, for the available
datasets from which at least one of these statistics
were available (Additional file 1: Appendix 5 for num-
bers in each study). One study [27] only reported sur-
vival data up to 9 years. Three studies [29, 40, 41]
only provided survival data for the final year of ana-
lyses in each respective study.
The forest plots provide a clear visualisation of the
trends between NPI categories within studies and, as
these are ordered by the mid-point of data collection,
differences in overall survival across time periods. The
observed pattern of overall survival by NPI category was
consistent across all datasets. Overall survival was seen
to be noticeably worse in NPI category 3 compared with
NPI categories 1 and 2. Visual inspection suggests sub-
stantial heterogeneity was observed in overall survival
between the available datasets. To illustrate, 5-year sur-
vival for NPI category 1 was as low as 81.25% [27] but
also as high as 99.26% [8]. Similarly, for NPI category 3,
the lowest 5-year overall survival was 24.56% [5] and the
highest was 83.55% [46].
Table 1 Summary of studies included in the review and
meta-analysis
Study details
Characteristic Systematic review Meta-analysis
Number of data
series (n = 30)
Number of data
series (n = 14)
Location
UK only 14 6
Europe 10 5
USA 1 0
Other 5 3
Size of sample
< 100 women 2 1
100 to 1000 women 10 6
1000 to 10,000
women
15 5
> 10,000 women 3 2
NPI categories
Three 18 8
Five 2 2
Other 10 4
Length of analysis
5 years 4 2
Between 5 and
10 years
3 1
10 years or more 23 11
Type of analysis
Parametric 4 0
Cox proportional
hazard model
20 9
Other
(Kaplan-Meier estimator)
6 5
Note: One study [1] reported data from ten European countries including the
UK; therefore, it is classified as ‘European’ study, not ‘UK only’
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Meta-analysis
The results of the meta-analysis are presented in
Table 2 for both 5-year survival and 10-year survival
statistics. There was evidence of considerable hetero-
geneity in the estimated survival statistics between
the included datasets. The I2 statistic indicated high
heterogeneity for each of the NPI category with
approximately 90 to 98% of the between-study vari-
ation estimated as being due to heterogeneity rather
than sampling variation, suggesting pooling of survival
estimates was inappropriate in all NPI categories.
Heterogeneity was also considered present based on
Q statistics which were statistically significant in all
instances. Tau statistics provide further evidence for
substantial heterogeneity with the reported standard
deviations of effect size being 2, 7 and 18 percentage
points (categories 1 to 3 respectively) for 5-year sur-
vival and 5, 11 and 14 percentage points for 10-year
survival.
Discussion
This review identified a substantial number of observa-
tional studies that aimed to generate estimates of the
overall survival of women diagnosed with early and/or
locally advanced breast cancer stratified by prognostic
category using NPI.
The strengths of this study include using a compre-
hensive, systematic review of the literature underpinned
by robust review methods (see Additional file 2:
PRISMA checklist). A broad electronic search strategy,
supplemented with hand searching of reference lists of
identified studies, to collate all the relevant studies and
datasets. The search strategy and inclusion criteria
achieved good sensitivity in identifying relevant studies.
The identified studies included patient cohorts from a
broad range of time periods for data collection, countries
and age groups. Critical appraisal following a standard
protocol found study reporting quality to be generally
satisfactory. A number of relevant identified studies had
to be excluded from the meta-analysis of overall survival
as the relevant data could not be extracted from the
published manuscript and authors were not able to pro-
vide the data required. The studies excluded at this stage
did not appear to suggest different outcomes for survival
compared to the included studies based on the more
limited information available. We focussed on cohort
studies and did not include randomized controlled trials
(RCT). RCT studies were considered unlikely to report
NPI-stratified survival estimates and are likely to have
applied more extensive exclusion criteria than cohort
studies. No formal quantitative assessment of publica-
tion bias was made. It is not clear in this context the
Fig. 2 Summary of time points for data collection (recruitment) for each dataset. Studies presented in order of publication date
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mechanism or result of publication bias that should be
expected because each study was testing different
hypothesis/hypotheses and in which the data extracted
for this study were presented descriptively.
A particular concern in evidence synthesis is whether
it was valid to pool data across multiple studies
[20].This exploratory meta-analysis investigated study
heterogeneity and demonstrated that this was too
severe for simple pooling of survival estimates to be
appropriate for the purposes of estimating survival in
the current population. It is of interest to understand
the factors driving the heterogeneity in survival esti-
mates; however, these data are insufficient to allow a
robust meta-regression or multilevel analysis to test hy-
potheses about such determinants. There are only a
small number of studies and many possible explanatory
variables, including some for which only weak surro-
gate markers would be available from study level data.
Investigation of the sources of between-study hetero-
geneity could be best achieved using an individual pa-
tient data meta-analysis to explore factors such as the
year of diagnosis of patients, country, screen detection
rate and age.
This study had a number of limitations. To provide
quantitative estimates of overall survival by NPI cat-
egory, given the relative age of some of the identified
studies, it was necessary to collate some data by visual
inspection of published survival curves. This process will
have introduced some measurement error. Due to lack
of detailed reporting of losses to follow-up it was also
necessary to assume that all studies had no loss to
follow-up, which could result in different degrees of
selection bias in the results if there were differential
losses to follow-up across studies. Based on the pub-
lished study protocols and the routine and often statu-
tory collection of mortality data, we believe that losses
to follow-up are likely to be minimal. Due to limitations
of available resources, non-English language studies and
those with insufficient reporting of data were excluded.
Furthermore, it was considered infeasible based on avail-
able resources and likely data sharing restrictions, to
attempt to collate individual patient data to address
Fig. 3 Forest plot of 5-year survival estimates from individual studies. Studies presented in order of mid-point of data collection earliest to most
recent. X-axis shows proportions of sample surviving at the specified time point
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some of these limitations. The resulting exclusions may
introduce some selection bias, but it is not possible to
know the impact of such a bias.
There were some observed differences in included
studies in the methods used to assess lymph node status
which is a key input to define NPI category. Originally,
node involvement for selected NPI category was assessed
using biopsy results of a lower axillary node, an apical
axillary node and a node from the internal mammary
chain. Node status was specified as one if the tumour
Fig. 4 Forest plot of 10-year survival estimates from individual studies. Studies presented in order of mid-point of data collection earliest to most
recent. X-axis shows proportions of sample surviving at the specified time point
Table 2 Results from the meta-analysis, pooled survival estimates and heterogeneity statistics
Statistic NPI 1 NPI 2 NPI 3
5-year follow-up
Fixed effects I-V estimate (95% CI) 0.953 (0.949, 0.957) 0.831 (0.825, 0.837) 0.535 (0.521, 0.549)
Random effects D-L estimate (95% CI) 0.943 (0.927, 0.96) 0.811 (0.769, 0.853) 0.565 (0.462, 0.668)
I2 (%) 89.6 97.2 97.7
Q 115.93 (P < 0.001) 422.5 (P < 0.001) 532.32 (P < 0.001)
Tau (% points) 2.45 7.28 18.25
10-year follow-up
Fixed effects I-V estimate (95% CI) 0.883 (0.877, 0.888) 0.682 (0.675, 0.689) 0.353 (0.341, 0.364)
Random effects D-L estimate (95% CI) 0.869 (0.837, 0.901) 0.674 (0.608, 0.74) 0.414 (0.329, 0.499)
I2 (%) 95.3 98.6 97.7
Q 213.56 (P < 0.001) 727.14 (P < 0.001) 427.44 (P < 0.001)
Tau (% points) 4.58 10.77 13.71
I-V inverse variance, D-L DerSimonian and Laird method
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was absent from all three nodes, two if tumour cells
were found in lower axillary node only, and three if
tumour cells were in the apical and/or internal mam-
mary node [4]. To increase usability of the NPI, Galea et
al. [5] suggested staging based on the number of in-
volved nodes from the single location as a viable alterna-
tive, which was subsequently used in later studies.
However, we believe this change in assessment of node
status was sufficiently similar to not introduce bias in
the analysis.
Conclusions
Precision medicine promises to deliver improved patient
outcomes through better understanding of patient and
disease heterogeneity, and ultimately better targeted
screening and therapeutic strategies. Moving the concept
of precision medicine into clinical practice requires
mechanisms to identify and stratify eligible patient pop-
ulations. Prognostic models are an important component
in such a mechanism because they allow an individual-
ized quantitative estimate of potential treatment benefit.
This systematic review and meta-analysis of NPI strati-
fied estimates of survival revealed a key challenge in the
design and evaluation of precision medicine interven-
tions; that substantial differences may exist between
studies estimating the relationship between a marker or
score and the outcome of interest. Heterogeneity of
study estimates should be investigated carefully for all
such interventions. This finding suggests a potential
additional burden on shared decision-making between
clinicians and patients. Achieving a better informed de-
cision is only possible if all of the available evidence is
correctly synthesized and clearly presented.
The results of this systematic review and meta-analysis
have implications for patients, clinicians, decision ana-
lysts and policy analysts requiring a prediction of
long-term overall survival, in women diagnosed with
early and/or locally advanced breast cancer. The ob-
served heterogeneity in overall survival estimates indi-
cates that it is important to make use of survival data
from an appropriate setting to provide reliable prognos-
tic information for use in clinical practice, and also in
decision-analytic model-based economic evaluations of
new treatments, screening programmes or prevention
strategies to inform health care resource allocation
decisions.
Endnotes
1A study that takes a group (cohort) of patients and
follows their progress over time in order to measure out-
comes such as disease or mortality rates and make com-
parisons according to the treatments or interventions
that patients received [47].
2Cancer reappearing after a remission [48].
3A proliferation of malignant-appearing cells of the
ducts and terminal lobular units of the breast that have
not breached the ductal basement membrane [49].
Additional files
Additional file 1: Appendix 1. NPI category cut-offs. Appendix 2.
Electronic search strategies. Appendix 3. Critical appraisal of accepted
studies. Appendix 4. Data extraction procedures. Appendix 5. Reported
five and ten-year survival per study dataset. (DOCX 71 kb)
Additional file 2: PRISMA checklist. (DOCX 21 kb)
Abbreviations
CASP: Critical Skills Appraisal Programme; HER-2: Human epidermal growth
factor receptor 2; NPI: Nottingham Prognostic Index; PROSPERO: International
prospective register of systematic reviews; RCT: Randomized controlled trial;
TNM: Tumour, nodes, metastases
Funding
The research leading to these results has received funding from the European
Union’s Seventh Framework Programme FP7 under grant agreement no.
306088. The funder had no role in the design of the study or collection,
analysis, and interpretation of data, or in writing the manuscript.
Availability of data and materials
The datasets generated and/or analysed during the current study are
available from the corresponding author on reasonable request.
Authors’ contributions
EG contributed to the design of the study, abstract and full text review;
design of the statistical analysis; and writing of the manuscript. AD contributed
to the literature search, abstract and full text review; data extraction; data
analysis; and writing of the manuscript. PH contributed to interpretation of the
results and writing of the manuscript. KP contributed to the design of the
study, interpretation of the results and writing of the manuscript. All authors
read and approved the final manuscript.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1The University of Edinburgh, Edinburgh, UK. 2Manchester Centre for Health
Economics, The University of Manchester, Manchester, UK.
Received: 16 August 2017 Accepted: 28 August 2018
References
1. Blamey RW, Hornmark-Stenstam B, Ball G, Blichert-Toft M, Cataliotti L,
Fourquet A, et al. ONCOPOOL - a European database for 16,944 cases of
breast cancer. Eur J Cancer Elsevier Ltd. 2010;46:56–71.
2. Lundin J, Lehtimäki T, Lundin M, Holli K, Elomaa L, Turpeenniemi-
Hujanen T, et al. Generalisability of survival estimates for patients with
breast cancer--a comparison across two population-based series. Eur J
Cancer. 2006;42:3228–35.
3. Sobin L, Gospodarowicz M, Wittekind C. TNM classification of malignant
tumours. 2011.
Gray et al. Systematic Reviews  (2018) 7:142 Page 8 of 9
4. Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC, et al.
A prognostic index in primary breast cancer. Br J Cancer. 1982;45:361–6.
5. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index
in primary breast cancer. Breast Cancer Res Treat. 1992;22:207–19.
6. Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G,
et al. PREDICT: a new UK prognostic model that predicts survival following
surgery for invasive breast cancer. Breast Cancer Res. 2010;12:R1.
7. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, et al.
Computer program to assist in making decisions about adjuvant therapy for
women with early breast cancer. J Clin Oncol. 2001;19:980–91.
8. Rakha EA, Soria D, Green a R, Lemetre C, Powe DG, Nolan CC, et al.
Nottingham Prognostic Index Plus (NPI+): a modern clinical decision
making tool in breast cancer. Br J Cancer. 2014;110:1688–97. Nature
Publishing Group
9. National Institute for Health and Care Excellence. CG80 early and locally
advanced breast cancer: diagnosis and treatment. 2009;
10. The Precision Medicine Initiative. Precision Medicine Initiative | The White
House. 2016. Available from: https://obamawhitehouse.archives.gov/
precision-medicine. [cited 8 May 2017]
11. Blamey RW. 4. The design and clinical use of the Nottingham Prognostic
Index in breast cancer. Breast. 1996;5:156–7. Elsevier
12. National Institute for Health and Care Excellence. Guide to the methods of
technology appraisal, Process and methods guides, vol. 9; 2013.
13. Sculpher MJ, Claxton K, Drummond M, McCabe C. Whither trial-based economic
evaluation for health care decision making? Health Econ. 2006;15:677–87.
14. University of York. NHS Centre for Reviews and Dissemination. Systematic
reviews: CRD’s guidance for undertaking reviews in health care. York: CRD,
University of York; 2009.
15. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al.
Meta-analysis of observational studies in epidemiology a proposal for
reporting. J Am Med Assoc. 2000;283:2008–12.
16. Nelson H, Tyne K, Naik A, Bougatsos C, Chan B, Nygren P, et al. Screening
for breast cancer: systematic evidence review update for the U.S. Preventive
Services Task Force. Evidence review update no. 74. 2009.
17. The CASP Team. Critical Appraisal Skills Programme (CASP) Cohort Study
Checklist. 2013. Available from: https://casp-uk.net/casp-tools-checklists/.
[cited 2 Feb 2017]
18. Guyot P, Ades AE, Ouwens MJNM, Welton NJ. Enhanced secondary analysis
of survival data: reconstructing the data from published Kaplan-Meier
survival curves. BMC Med Res Methodol. 2012;12:9.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials.
1986;7:177–88.
20. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions
version 5.1.0 [updated march 2011]. The Cochrane Collaboration; 2011.
21. Borenstein M, Higgins JPT, Hedges LV, Rothstein HR. Basics of meta-
analysis: I2 is not an absolute measure of heterogeneity. Res Synth
Methods. 2017;8:5–18.
22. Gavaghan DJ, Moore RA, McQuay HJ. An evaluation of homogeneity tests in
meta-analyses in pain using simulations of individual patient data. Pain.
2000;85:415–24.
23. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis.
Stat Med. 2002;21:1539–58.
24. Rice K, Higgins JPT, Lumley T. A re-evaluation of fixed effect(s) meta-analysis.
J R Stat Soc Ser A Stat Soc. 2018;181:205–27.
25. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian approaches to clinical trials
and health care evaluation. Stat. Pract. 2004.
26. Blamey RW, Ellis IO, Pinder SE, Lee AHS, Macmillan RD, Morgan DAL, et al.
Survival of invasive breast cancer according to the Nottingham Prognostic
Index in cases diagnosed in 1990-1999. Eur J Cancer. 2007;43:1548–55.
27. Suen D, Chow LWC. Prognostic contribution of the HER-2 oncogene
overexpression to the Nottingham Prognostic Index in breast cancer.
Biomed Pharmacother. 2006;60:293–7.
28. Jarman IH, Etchells TA, Martín JD, Lisboa PJG. An integrated framework for
risk profiling of breast cancer patients following surgery. Artif Intell Med.
2008;42:165–88.
29. Wishart GC, Greenberg DC, Britton PD, Chou P, Brown CH, Purushotham AD,
et al. Screen-detected vs symptomatic breast cancer: is improved survival
due to stage migration alone? Br J Cancer. 2008;98:1741–4.
30. Anderson TJ, Alexander FE, Lamb J, Smith A, Forrest AP. Pathology
characteristics that optimize outcome prediction of a breast screening trial.
Br J Cancer. 2000;83:487–92.
31. Sauerbrei W, Hübner K, Schmoor C, Schumacher M. Validation of existing
and development of new prognostic classification schemes in node
negative breast cancer. Breast Cancer Res Treat. 1997;42:149–63.
32. Hwang KT, Woo JW, Shin HC, Kim HS, Ahn SK, Moon HG, et al.
Prognostic influence of BCL2 expression in breast cancer. Int J Cancer.
2012;131:E1109–19.
33. Campbell H, Gray A, Harris A, Briggs A, Taylor M. Estimation and external
validation of a new prognostic model for predicting recurrence-free survival
for early breast cancer patients in the UK. Br. J. Cancer. 2010;103:776–86.
Nature Publishing Group
34. Sundquist M, Thorstenson S, Brudin L, Nordenskjold B, Group SESBCS.
Applying the Nottingham Prognostic Index to a Swedish breast cancer
population. Breast Cancer Res Treat. 1999;53:1–8.
35. Hasebe T, Sasaki S, Imoto S, Wada N, Ishii G, Ochiai A. Primary tumour–
vessel tumour–nodal tumour classification for patients with invasive ductal
carcinoma of the breast. Br J Cancer. 2005;92:847–56.
36. Quintyne KI, Woulfe B, Coffey JC, Gupta RK. Correlation between Nottingham
Prognostic Index and Adjuvant! Online prognostic tools in patients with early-
stage breast cancer in Mid-Western Ireland. Clin Breast Cancer. 2013;13:233–8.
Elsevier
37. Winzer KJ, Buchholz A, Schumacher M, Sauerbrei W. Improving the
prognostic ability through better use of standard clinical data - the
Nottingham Prognostic Index as an example. PLoS One. 2016;11:e0149977.
38. Kollias J, Elston CW, Ellis IO, Robertson JF, Blamey RW. Early-onset breast
cancer--histopathological and prognostic considerations. Br J Cancer. 1997;
75:1318–23.
39. Kollias J, Murphy CA, Elston CW, Ellis IO, Robertson JFR, Blamey RW, et al.
The prognosis of small primary breast cancers. Eur J Cancer. 1999;35:908–12.
40. Blamey RW, Pinder SE, Ball GR, Ellis IO, Elston CW, Mitchell MJ, et al. Reading
the prognosis of the individual with breast cancer. Eur J Cancer. 2007;43:
1545–7.
41. Allgood PC, Duffy SW, Kearins O, O’Sullivan E, Tappenden N, Wallis MG,
et al. Explaining the difference in prognosis between screen-detected and
symptomatic breast cancers. Br J Cancer. 2011;104:1680–5.
42. Callagy GM, Pharoah PD, Pinder SE, Hsu FD, Nielsen TO, Ragaz J, et al. Bcl-2
is a prognostic marker in breast cancer independently of the Nottingham
Prognostic Index. Clin Cancer Res. 2006;12:2468–75.
43. Rejali M, Tazhibi M, Mokarian F, Gharanjik N, Mokarian R. The performance
of the Nottingham Prognosis Index and the adjuvant online decision
making tool for prognosis in early-stage breast cancer patients. Int J Prev
Med. 2015;6:93.
44. Bundred NJ, Prasad R, Morris J, Knox WF, Byrne G, Cheung S, et al. Are
symptomatic guidelines for chemotherapy appropriate to ER-positive
screen-detected breast cancer (SDBC)? Breast Cancer Res Treat. 2013;138:
359–68.
45. Hansen S, Grabau DA, Sørensen FB, Bak M, Vach W, Rose C. Vascular grading
of angiogenesis: prognostic significance in breast cancer. Br J Cancer. 2000;
82:339–47.
46. Fong Y, Evans J, Brook D, Kenkre J, Jarvis P, Gower-Thomas K. The
Nottingham Prognostic Index: five- and ten-year data for all-cause survival
within a screened population. Ann R Coll Surg Engl. 2015;97:137–9.
47. National Institute for Health and Care Excellence. Glossary | NICE. NICE;
Available from: https://www.nice.org.uk/glossary. [cited 2 Feb 2017]
48. Stedman TL. Stedman’s medical dictionary. Philadelphia: Lippincott Williams
& Wilkins; 2006.
49. Olivotto I, Levine M, Steering Committee on Clinical Practice Guidelines for
the Care and Treatment of Breast Cancer. Clinical practice guidelines for the
care and treatment of breast cancer: the management of ductal carcinoma
in situ (summary of the 2001 update). CMAJ. 2001;165:912–3.
Gray et al. Systematic Reviews  (2018) 7:142 Page 9 of 9
